Ahead of Alpharadin Filings, Algeta Seeks $45M Financing

With regulatory filings for its prostate cancer therapy, Alpharadin (radium-223 chloride), expected in mid-2012, Algeta ASA is seeking up to NOK260 million (US$45.4 million) in a private placement to enable it to establish a commercial base in the U.S. in advance of a product launch and to continue research and development of its second line of alpha emitters, based on thorium-227.